Question 1

How do I determine the right peptide dose for my patient?

Accepted Answer

Peptide dosing should be individualized based on patient factors including body weight, clinical indication, treatment goals, and response to therapy. Our dosing protocols provide evidence-based starting points referenced to primary literature, but prescribers should exercise clinical judgment and monitor patient response to optimize dosing.

Question 2

What is a peptide loading dose?

Accepted Answer

A loading dose is a higher initial dose given at the start of therapy to rapidly achieve therapeutic tissue levels. Many peptide protocols use loading phases (typically 2-4 weeks) followed by lower maintenance doses. This approach is common with peptides like BPC-157 and TB-500 where tissue saturation may improve clinical outcomes.

Question 3

How long should peptide therapy last?

Accepted Answer

Treatment duration varies by peptide and indication. Some protocols are time-limited (e.g., BPC-157 for injury repair: 4-12 weeks), while others may be ongoing (e.g., growth hormone secretagogues for anti-aging). Duration should be determined by clinical response, with periodic reassessment of treatment goals and monitoring parameters.

Question 4

What routes of administration are used for peptides?

Accepted Answer

Common routes include subcutaneous injection (most frequent), intramuscular injection, oral administration, intranasal delivery, and topical application. The optimal route depends on the specific peptide, its bioavailability by different routes, patient preference, and clinical indication. Subcutaneous injection is the most common for most peptide therapeutics.

Peptide	Indication	Loading Dose	Maintenance	Duration	Notes
AOD-9604 SubQ \| Daily, morning fasted	Fat loss / Body composition	300mcg/day	300mcg/day	12-24 weeks	Fragment of HGH (176-191) targeting fat metabolism without growth effects. Best administered in fasted state. Recently removed from FDA Category 2 list (Sept 2024).
BPC-157 SubQ \| Daily (split AM/PM)	Gut healing	250-500mcg/day	250mcg/day	4-8 weeks	Oral administration also effective for GI indications. Consider splitting dose to twice daily for improved efficacy. Best taken on empty stomach.
BPC-157 SubQ \| Daily	Injury repair / Musculoskeletal	500mcg/day	250mcg/day	6-12 weeks	Local injection near injury site preferred when possible. Systemic administration also effective. Consider combining with TB-500 for enhanced tissue repair.
Ipamorelin/CJC-1295 SubQ \| Daily, before bed	Anti-aging / GH optimization	200mcg each	100mcg each	Ongoing (cycle 3-6 months on, 1 month off)	Administer on empty stomach, at least 2 hours after last meal. Evening dosing aligns with natural GH pulse. CJC-1295 with DAC can be dosed less frequently (2x/week).
PT-141 (Bremelanotide) SubQ \| PRN, 45 minutes before activity	Sexual dysfunction	1.75mg	PRN (as needed)	As needed	FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Max 1 dose per 24 hours, max 8 doses per month. Common side effect: transient nausea, flushing.
Semaglutide SubQ \| Once weekly	Weight loss / Obesity	0.25mg/week (weeks 1-4)	Up to 2.4mg/week	Ongoing	Titrate monthly: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg. Slower titration reduces GI side effects. Take on same day each week. FDA-approved as Wegovy for chronic weight management.
TB-500 SubQ \| 2x/week loading, 1x/week maintenance	Tissue repair / Wound healing	2.5mg twice weekly	2.5mg weekly	4-6 weeks loading, then maintenance	Loading phase is critical for tissue saturation. Can be administered anywhere subcutaneously - systemic distribution occurs. Often stacked with BPC-157.
Tesamorelin SubQ \| Daily	Lipodystrophy / Visceral fat reduction	2mg/day	2mg/day	26 weeks (FDA-approved course)	FDA-approved for HIV-associated lipodystrophy (Egrifta). Inject into abdomen. Rotate injection sites. Monitor IGF-1 levels. Contraindicated in active malignancy.

Peptide Dosing Protocols

AOD-9604

BPC-157

BPC-157

Ipamorelin/CJC-1295

PT-141 (Bremelanotide)

Semaglutide

TB-500

Tesamorelin

Frequently Asked Questions

Need More Detailed Information?